HEADER TRANSCRIPTION 19-NOV-10 2XYW TITLE NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL TITLE 2 DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA TITLE 3 AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN, RESIDUES 165-441; COMPND 5 SYNONYM: NUCI, NUCLEAR HORMONE RECEPTOR 1, NUCLEAR RECEPTOR SUBFAMILY COMPND 6 1 GROUP C MEMBER 2, PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR BETA, COMPND 7 PPAR-DELTA, NUC1, PPAR-BETA; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3) KEYWDS DNA-BINDING, TRANSCRIPTION, TRANSCRIPTION REGULATION, RECEPTOR, KEYWDS 2 ACTIVATOR, ZINC-FINGER EXPDTA X-RAY DIFFRACTION AUTHOR J.-P.MARQUETTE,M.MATHIEU REVDAT 3 29-JUL-20 2XYW 1 COMPND REMARK HETNAM SITE REVDAT 2 25-MAY-11 2XYW 1 JRNL REVDAT 1 23-FEB-11 2XYW 0 JRNL AUTH S.KEIL,H.MATTER,K.SCHONAFINGER,M.GLIEN,M.MATHIEU, JRNL AUTH 2 J.-P.MARQUETTE,N.MICHOT,S.HAAG-DIERGARTEN,M.URMANN,W.WENDLER JRNL TITL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL JRNL TITL 2 DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA JRNL TITL 3 / DELTA AGONISTS WITH HIGH POTENCY AND IN-VIVO EFFICACY JRNL REF CHEMMEDCHEM V. 6 633 2011 JRNL REFN ISSN 1860-7179 JRNL PMID 21400663 JRNL DOI 10.1002/CMDC.201100047 REMARK 2 REMARK 2 RESOLUTION. 3.14 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.9.3 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 3.14 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 14.99 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 99.7 REMARK 3 NUMBER OF REFLECTIONS : 12134 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.191 REMARK 3 R VALUE (WORKING SET) : 0.188 REMARK 3 FREE R VALUE : 0.247 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.790 REMARK 3 FREE R VALUE TEST SET COUNT : 581 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 6 REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 3.14 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 3.44 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.65 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2876 REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2066 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2733 REMARK 3 BIN R VALUE (WORKING SET) : 0.2035 REMARK 3 BIN FREE R VALUE : 0.2651 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.97 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 143 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4244 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 108 REMARK 3 SOLVENT ATOMS : 0 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 80.30 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 57.17 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.37120 REMARK 3 B22 (A**2) : -0.69070 REMARK 3 B33 (A**2) : -0.68050 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.93250 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.530 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : NULL REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.442 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : NULL REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : NULL REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.923 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.848 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 4448 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 6012 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 1540 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : 124 ; 2.000 ; HARMONIC REMARK 3 GENERAL PLANES : 628 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 4448 ; 20.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : 2 ; 5.000 ; SEMIHARMONIC REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 582 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 5227 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.010 REMARK 3 BOND ANGLES (DEGREES) : 1.16 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 2.44 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 21.83 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2XYW COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 19-NOV-10. REMARK 100 THE DEPOSITION ID IS D_1290046337. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 26-JUN-06 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID14-4 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9795 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 12270 REMARK 200 RESOLUTION RANGE HIGH (A) : 3.140 REMARK 200 RESOLUTION RANGE LOW (A) : 96.670 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : 0.07000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 15.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 3.14 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.31 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.8 REMARK 200 DATA REDUNDANCY IN SHELL : 3.70 REMARK 200 R MERGE FOR SHELL (I) : 0.23000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 5.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: IN-HOUSE STRUCTURE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 57.42 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.91 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PEG8000 8%,BISTRISPROPANE 40MM, PH7, REMARK 280 PROPANEDIOL 5%, KCL 300MM, DTT 5MM, EDTA 1MM, PH 7.0 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 46.60900 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 154 REMARK 465 LYS A 155 REMARK 465 LYS A 156 REMARK 465 GLY A 157 REMARK 465 HIS A 158 REMARK 465 HIS A 159 REMARK 465 HIS A 160 REMARK 465 HIS A 161 REMARK 465 HIS A 162 REMARK 465 HIS A 163 REMARK 465 GLY A 164 REMARK 465 GLY A 165 REMARK 465 SER A 166 REMARK 465 GLN A 167 REMARK 465 TYR A 168 REMARK 465 ASN A 169 REMARK 465 PRO A 170 REMARK 465 GLN A 171 REMARK 465 VAL A 172 REMARK 465 ALA A 173 REMARK 465 ALA A 205 REMARK 465 SER A 206 REMARK 465 HIS A 207 REMARK 465 THR A 208 REMARK 465 TYR A 441 REMARK 465 MET B 154 REMARK 465 LYS B 155 REMARK 465 LYS B 156 REMARK 465 GLY B 157 REMARK 465 HIS B 158 REMARK 465 HIS B 159 REMARK 465 HIS B 160 REMARK 465 HIS B 161 REMARK 465 HIS B 162 REMARK 465 HIS B 163 REMARK 465 GLY B 164 REMARK 465 GLY B 165 REMARK 465 SER B 166 REMARK 465 GLN B 167 REMARK 465 TYR B 168 REMARK 465 ASN B 169 REMARK 465 PRO B 170 REMARK 465 GLN B 171 REMARK 465 VAL B 172 REMARK 465 ALA B 173 REMARK 465 ALA B 205 REMARK 465 SER B 206 REMARK 465 HIS B 207 REMARK 465 THR B 208 REMARK 465 TYR B 441 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 VAL A 227 92.36 -61.97 REMARK 500 LYS A 239 -61.56 -121.54 REMARK 500 SER A 272 -27.26 -159.92 REMARK 500 ASP A 360 4.11 -68.45 REMARK 500 ASN A 366 65.54 -101.09 REMARK 500 LYS A 438 -73.77 -42.55 REMARK 500 ASP A 439 65.81 -114.65 REMARK 500 VAL B 227 92.07 -56.28 REMARK 500 LYS B 239 -61.37 -121.46 REMARK 500 SER B 272 -27.39 -159.30 REMARK 500 ASP B 360 4.02 -68.17 REMARK 500 ASN B 366 65.22 -101.27 REMARK 500 LYS B 438 -76.77 -50.12 REMARK 500 ASP B 439 67.95 -105.47 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1Y0S RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF PPAR DELTA COMPLEXED WITH GW2331 REMARK 900 RELATED ID: 2AWH RELATED DB: PDB REMARK 900 HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1 REMARK 900 RELATED ID: 2XYX RELATED DB: PDB REMARK 900 NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL REMARK 900 DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA REMARK 900 AGONISTS WITH HIGH POTENCY AND IN -VIVO EFFICACY REMARK 900 RELATED ID: 2B50 RELATED DB: PDB REMARK 900 HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 2 REMARK 900 RELATED ID: 2BAW RELATED DB: PDB REMARK 900 HUMAN NUCLEAR RECEPTOR-LIGAND COMPLEX 1 REMARK 900 RELATED ID: 2GWX RELATED DB: PDB REMARK 900 MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR- REMARK 900 ACTIVATED RECEPTORS REMARK 900 RELATED ID: 2XYJ RELATED DB: PDB REMARK 900 NOVEL SULFONYLTHIADIAZOLES WITH AN UNUSUAL BINDING MODE AS PARTIAL REMARK 900 DUAL PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) GAMMA-DELTA REMARK 900 AGONISTS WITH HIGH POTENCY AND IN -VIVO EFFICACY REMARK 900 RELATED ID: 1GWX RELATED DB: PDB REMARK 900 MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR- REMARK 900 ACTIVATED RECEPTORS REMARK 900 RELATED ID: 2J14 RELATED DB: PDB REMARK 900 3,4,5-TRISUBSTITUTED ISOXAZOLES AS NOVEL PPARDELTA AGONISTS: PART2 REMARK 900 RELATED ID: 3GWX RELATED DB: PDB REMARK 900 MOLECULAR RECOGNITION OF FATTY ACIDS BY PEROXISOME PROLIFERATOR- REMARK 900 ACTIVATED RECEPTORS REMARK 999 REMARK 999 SEQUENCE REMARK 999 NTERMINAL HIS-TAG DBREF 2XYW A 165 441 UNP Q03181 PPARD_HUMAN 165 441 DBREF 2XYW B 165 441 UNP Q03181 PPARD_HUMAN 165 441 SEQADV 2XYW MET A 154 UNP Q03181 EXPRESSION TAG SEQADV 2XYW LYS A 155 UNP Q03181 EXPRESSION TAG SEQADV 2XYW LYS A 156 UNP Q03181 EXPRESSION TAG SEQADV 2XYW GLY A 157 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS A 158 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS A 159 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS A 160 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS A 161 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS A 162 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS A 163 UNP Q03181 EXPRESSION TAG SEQADV 2XYW GLY A 164 UNP Q03181 EXPRESSION TAG SEQADV 2XYW MET B 154 UNP Q03181 EXPRESSION TAG SEQADV 2XYW LYS B 155 UNP Q03181 EXPRESSION TAG SEQADV 2XYW LYS B 156 UNP Q03181 EXPRESSION TAG SEQADV 2XYW GLY B 157 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS B 158 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS B 159 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS B 160 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS B 161 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS B 162 UNP Q03181 EXPRESSION TAG SEQADV 2XYW HIS B 163 UNP Q03181 EXPRESSION TAG SEQADV 2XYW GLY B 164 UNP Q03181 EXPRESSION TAG SEQRES 1 A 288 MET LYS LYS GLY HIS HIS HIS HIS HIS HIS GLY GLY SER SEQRES 2 A 288 GLN TYR ASN PRO GLN VAL ALA ASP LEU LYS ALA PHE SER SEQRES 3 A 288 LYS HIS ILE TYR ASN ALA TYR LEU LYS ASN PHE ASN MET SEQRES 4 A 288 THR LYS LYS LYS ALA ARG SER ILE LEU THR GLY LYS ALA SEQRES 5 A 288 SER HIS THR ALA PRO PHE VAL ILE HIS ASP ILE GLU THR SEQRES 6 A 288 LEU TRP GLN ALA GLU LYS GLY LEU VAL TRP LYS GLN LEU SEQRES 7 A 288 VAL ASN GLY LEU PRO PRO TYR LYS GLU ILE SER VAL HIS SEQRES 8 A 288 VAL PHE TYR ARG CYS GLN CYS THR THR VAL GLU THR VAL SEQRES 9 A 288 ARG GLU LEU THR GLU PHE ALA LYS SER ILE PRO SER PHE SEQRES 10 A 288 SER SER LEU PHE LEU ASN ASP GLN VAL THR LEU LEU LYS SEQRES 11 A 288 TYR GLY VAL HIS GLU ALA ILE PHE ALA MET LEU ALA SER SEQRES 12 A 288 ILE VAL ASN LYS ASP GLY LEU LEU VAL ALA ASN GLY SER SEQRES 13 A 288 GLY PHE VAL THR ARG GLU PHE LEU ARG SER LEU ARG LYS SEQRES 14 A 288 PRO PHE SER ASP ILE ILE GLU PRO LYS PHE GLU PHE ALA SEQRES 15 A 288 VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU SEQRES 16 A 288 ALA LEU PHE ILE ALA ALA ILE ILE LEU CYS GLY ASP ARG SEQRES 17 A 288 PRO GLY LEU MET ASN VAL PRO ARG VAL GLU ALA ILE GLN SEQRES 18 A 288 ASP THR ILE LEU ARG ALA LEU GLU PHE HIS LEU GLN ALA SEQRES 19 A 288 ASN HIS PRO ASP ALA GLN TYR LEU PHE PRO LYS LEU LEU SEQRES 20 A 288 GLN LYS MET ALA ASP LEU ARG GLN LEU VAL THR GLU HIS SEQRES 21 A 288 ALA GLN MET MET GLN ARG ILE LYS LYS THR GLU THR GLU SEQRES 22 A 288 THR SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP SEQRES 23 A 288 MET TYR SEQRES 1 B 288 MET LYS LYS GLY HIS HIS HIS HIS HIS HIS GLY GLY SER SEQRES 2 B 288 GLN TYR ASN PRO GLN VAL ALA ASP LEU LYS ALA PHE SER SEQRES 3 B 288 LYS HIS ILE TYR ASN ALA TYR LEU LYS ASN PHE ASN MET SEQRES 4 B 288 THR LYS LYS LYS ALA ARG SER ILE LEU THR GLY LYS ALA SEQRES 5 B 288 SER HIS THR ALA PRO PHE VAL ILE HIS ASP ILE GLU THR SEQRES 6 B 288 LEU TRP GLN ALA GLU LYS GLY LEU VAL TRP LYS GLN LEU SEQRES 7 B 288 VAL ASN GLY LEU PRO PRO TYR LYS GLU ILE SER VAL HIS SEQRES 8 B 288 VAL PHE TYR ARG CYS GLN CYS THR THR VAL GLU THR VAL SEQRES 9 B 288 ARG GLU LEU THR GLU PHE ALA LYS SER ILE PRO SER PHE SEQRES 10 B 288 SER SER LEU PHE LEU ASN ASP GLN VAL THR LEU LEU LYS SEQRES 11 B 288 TYR GLY VAL HIS GLU ALA ILE PHE ALA MET LEU ALA SER SEQRES 12 B 288 ILE VAL ASN LYS ASP GLY LEU LEU VAL ALA ASN GLY SER SEQRES 13 B 288 GLY PHE VAL THR ARG GLU PHE LEU ARG SER LEU ARG LYS SEQRES 14 B 288 PRO PHE SER ASP ILE ILE GLU PRO LYS PHE GLU PHE ALA SEQRES 15 B 288 VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP LEU SEQRES 16 B 288 ALA LEU PHE ILE ALA ALA ILE ILE LEU CYS GLY ASP ARG SEQRES 17 B 288 PRO GLY LEU MET ASN VAL PRO ARG VAL GLU ALA ILE GLN SEQRES 18 B 288 ASP THR ILE LEU ARG ALA LEU GLU PHE HIS LEU GLN ALA SEQRES 19 B 288 ASN HIS PRO ASP ALA GLN TYR LEU PHE PRO LYS LEU LEU SEQRES 20 B 288 GLN LYS MET ALA ASP LEU ARG GLN LEU VAL THR GLU HIS SEQRES 21 B 288 ALA GLN MET MET GLN ARG ILE LYS LYS THR GLU THR GLU SEQRES 22 B 288 THR SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS ASP SEQRES 23 B 288 MET TYR HET 08S A1441 34 HET BOG A1442 20 HET 08S B1441 34 HET BOG B1442 20 HETNAM 08S 3-CHLORO-6-FLUORO-N-[2-[4-[(5-PROPAN-2-YL-1,3,4- HETNAM 2 08S THIADIAZOL-2-YL)SULFAMOYL]PHENYL]ETHYL]-1- HETNAM 3 08S BENZOTHIOPHENE-2-CARBOXAMIDE HETNAM BOG OCTYL BETA-D-GLUCOPYRANOSIDE FORMUL 3 08S 2(C22 H20 CL F N4 O3 S3) FORMUL 4 BOG 2(C14 H28 O6) HELIX 1 1 ASP A 174 PHE A 190 1 17 HELIX 2 2 THR A 193 LEU A 201 1 9 HELIX 3 3 ASP A 215 LEU A 226 1 12 HELIX 4 4 LEU A 231 LEU A 235 5 5 HELIX 5 5 GLU A 240 ILE A 267 1 28 HELIX 6 6 PHE A 274 ALA A 295 1 22 HELIX 7 7 ARG A 314 SER A 319 1 6 HELIX 8 8 ILE A 328 ALA A 340 1 13 HELIX 9 9 ASP A 344 LEU A 357 1 14 HELIX 10 10 ASN A 366 HIS A 389 1 24 HELIX 11 11 TYR A 394 GLU A 424 1 31 HELIX 12 12 HIS A 430 TYR A 437 1 8 HELIX 13 13 ASP B 174 PHE B 190 1 17 HELIX 14 14 THR B 193 LEU B 201 1 9 HELIX 15 15 ASP B 215 GLY B 225 1 11 HELIX 16 16 LEU B 231 LEU B 235 5 5 HELIX 17 17 GLU B 240 ILE B 267 1 28 HELIX 18 18 PHE B 274 ALA B 295 1 22 HELIX 19 19 ARG B 314 SER B 319 1 6 HELIX 20 20 ILE B 328 ALA B 340 1 13 HELIX 21 21 ASP B 344 LEU B 357 1 14 HELIX 22 22 ASN B 366 HIS B 389 1 24 HELIX 23 23 TYR B 394 GLU B 424 1 31 HELIX 24 24 HIS B 430 ASP B 439 1 10 SHEET 1 AA 4 PHE A 211 ILE A 213 0 SHEET 2 AA 4 GLY A 310 THR A 313 1 O PHE A 311 N ILE A 213 SHEET 3 AA 4 GLY A 302 VAL A 305 -1 O LEU A 303 N VAL A 312 SHEET 4 AA 4 VAL A 298 ASN A 299 -1 O ASN A 299 N GLY A 302 SHEET 1 BA 4 PHE B 211 ILE B 213 0 SHEET 2 BA 4 GLY B 310 THR B 313 1 O PHE B 311 N ILE B 213 SHEET 3 BA 4 GLY B 302 VAL B 305 -1 O LEU B 303 N VAL B 312 SHEET 4 BA 4 VAL B 298 ASN B 299 -1 O ASN B 299 N GLY B 302 CISPEP 1 LYS A 322 PRO A 323 0 7.37 CISPEP 2 LYS B 322 PRO B 323 0 7.74 CRYST1 39.368 93.218 97.473 90.00 97.31 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.025401 0.000000 0.003258 0.00000 SCALE2 0.000000 0.010728 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010343 0.00000